Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$189.07 - $236.8 $2.33 Million - $2.91 Million
-12,300 Reduced 65.78%
6,400 $1.24 Million
Q2 2024

Aug 14, 2024

SELL
$190.52 - $236.72 $8.97 Million - $11.1 Million
-47,100 Reduced 71.58%
18,700 $4.34 Million
Q1 2024

May 15, 2024

BUY
$212.02 - $267.71 $10.8 Million - $13.6 Million
50,900 Added 341.61%
65,800 $14.2 Million
Q4 2023

Feb 14, 2024

BUY
$222.59 - $267.94 $1.29 Million - $1.55 Million
5,800 Added 63.74%
14,900 $3.86 Million
Q3 2023

Nov 14, 2023

BUY
$253.3 - $285.89 $1.29 Million - $1.46 Million
5,100 Added 127.5%
9,100 $2.34 Million
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $82,575 - $95,418
300 Added 8.11%
4,000 $1.14 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $359,184 - $409,275
1,400 Added 60.87%
3,700 $1.03 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $580,612 - $705,456
2,300 New
2,300 $636,000
Q2 2020

Aug 14, 2020

SELL
$258.66 - $342.55 $232,794 - $308,295
-900 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $2.2 Million - $2.8 Million
-8,200 Reduced 90.11%
900 $285,000
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $4.49 Million - $6.2 Million
-20,400 Reduced 69.15%
9,100 $2.7 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $2.96 Million - $3.32 Million
13,600 Added 85.53%
29,500 $6.87 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $3.27 Million - $3.6 Million
14,900 Added 1490.0%
15,900 $3.72 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $216,710 - $338,960
1,000 New
1,000 $236,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.